Multiple sclerosis drug with lethal side effects approved by FDA panel
By Elizabeth Rhein
Published on April 06, 2006
In February of 2005, multiple sclerosis drug Tysabri was pulled from the market shortly after it was approved, after it was found to cause a rare brain disease called progressive multifocal leukoencephalopathy, or PML.
Now, in response to requests from both multiple sclerosis patients and their doctors, an FDA advisory panel has agreed to recommend that the FDA allow the drug to be returned to market. Proponents of the medication argue that the risk of PML is low enough (about one in 1,000) that patients and doctors should be allowed to choose between the risk of the brain disease and the considerable benefits offered by the drug.
There is no way to predict which patients will contract PML, although the federal committee believes strongly that combining Tysabri with other multiple sclerosis drugs increases the risk of getting the disease.
It is anticipated that the FDA will go along with the panel's recommendation.
Keyword Tags:

Comments
James Daniels, 6 days ago
James Daniels, 6 days ago